Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/2/2026

1. NKE
2. TSLA
3. MU
4. SPY
5. SPCX
6. META
7. ABVX
8. NVDA
9. BE
10. STZ

Go back to Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia
(NASDAQ: NERV) Delayed: 5.15 -0.4 (7.21%)
Previous Close $5.55    52 Week High $15.84 
Open $5.55    52 Week Low $3.45 
Day High $5.55    P/E N/A 
Day Low $5.13    EPS $0.00 
Volume 124,225